Standard Biotools (LAB) Cash from Investing Activities (2010 - 2026)

Standard Biotools (LAB) has 17 years of Cash from Investing Activities data on file, last reported at $191.1 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $191.1 million, up 1206.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $203.9 million (up 241.36% YoY), and the FY2025 annual result was $27.4 million, down 92.45% from the prior year.
• Cash from Investing Activities rose to $191.1 million in Q1 2026 per LAB's latest filing, from -$8.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $318.1 million in Q1 2024 and troughed at -$138.2 million in Q2 2022.
• A 5-year average of $30.2 million and a median of $14.6 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 1419.96% in 2022, then surged 5071.66% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at $40.2 million in 2022, then plunged by 132.59% to -$13.1 million in 2023, then soared by 296.13% to $25.7 million in 2024, then sank by 131.25% to -$8.0 million in 2025, then jumped by 2476.74% to $191.1 million in 2026.
• Business Quant data shows LAB's Cash from Investing Activities at $191.1 million in Q1 2026, -$8.0 million in Q4 2025, and -$6.7 million in Q3 2025.